A preclinical approach for gene therapy of β-thalassemia

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 134-140

  Breda, Laura ^a   Kleinert, Dorothy A ^a   Casu, Carla ^a   Casula, Laura ^a   Cartegni, Luca ^b   Fibach, Eitan ^c   Mancini, Irene ^d   Giardina, Patricia J ^a   Gambari, Roberto ^d   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

erythroid progenitor cells; gene therapy; hemoglobin; lentiviral vectors; globin; thalassemia

Indexed keywords

BETA GLOBIN; CYCLOSPORIN A; ERYTHROPOIETIN; GLUTAMINE; HEMOGLOBIN; PHOSPHOGLYCERATE DEHYDROGENASE; STEM CELL FACTOR; STREPTOMYCIN;

ANEMIA; BETA THALASSEMIA; CELL CULTURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ERYTHROID CELL; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; LENTIVIRINAE; MEDICAL DECISION MAKING; NONHUMAN; STEM CELL; THALASSEMIA MAJOR; TRANSGENE;

EID: 77955863845     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05594.x     Document Type: Conference Paper

References (26)

1. Steinberg, M.H. et al. 2001. Disorders of hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge University Press. Cambridge, UK.
2. Maquat, L.E. et al. 1981. Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell 27: 543-553.
3. Romao, L. et al. 2000. Nonsense mutations in the human beta-globin gene lead to unexpected levels of cytoplasmic mRNA accumulation. Blood 96: 2895-2901.
4. Spritz, R.A. et al. 1981. Base substitution in an intervening sequence of a beta+-thalassemic human globin gene. Proc. Natl. Acad. Sci. USA 78: 2455-2459.
5. May, C. et al. 2000. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406: 82-86.
6. May, C. et al. 2002. Successful treatment of murine betathalassemia intermedia by transfer of the human beta-globin gene. Blood 99: 1902-1908.
7. Rivella, S. & M. Sadelain. 2002. Therapeutic globin gene delivery using lentiviral vectors. Curr. Opin. Mol. Ther. 4: 505-514.
8. Breda, L. & S. Rivella. 2003. Development of new mouse models to study globin gene regulation. Minerva Biotecnologica. 15: 107-121.
9. Rivella, S. et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta -globin gene transfer. Blood 101: 2932-2939.
10. Rivella, S. & E. Rachmilewitz. 2009. Future alternative therapies for-thalassemia. Expert Rev. Hematol. 2: 685-697.
11. Breda, L., R. Gambari & S. Rivella. 2009. Gene therapy in thalassemia and hemoglobinopathies. Mediterr. J. Hematol. Infect. Dis. 1.
12. Ciavatta, D.J. et al. 1995. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc. Natl. Acad. Sci. USA 92: 9259-9263.
13. Yang, B. et al. 1995. A mouse model for beta 0-thalassemia. Proc. Natl. Acad. Sci. USA 92: 11608-11612.
14. Bank,A., R. Dorazio&P. Leboulch. 2005.Aphase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann. N.Y. Acad. Sci. 1054: 308-316.
15. Kaiser, J. 2009. Gene therapy. Beta-thalassemia treatment succeeds, with a caveat. Science 326: 1468-1469.
16. Breda, L. et al. 2009. Following Beta-Globin Gene Transfer, the Production ofHemoglobinDepends upon the -Thalassemia Genotype: The Traffic Jam Hypothesis. American Society of Gene Therapy (ASGT). San Diego.
17. Rivella, S. et al. 2000. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. 74: 4679-4687.
18. Breda, L. et al. 2009. Following beta-globin gene transfer, the production of hemoglobin depends upon the betathalassemia genotype. Blood 114: 978.
19. Liu, J. et al. 1992. SpecificNF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66: 3883-3887.
20. Ross, E.K. et al. 1991. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J. Virol. 65: 4350-4358.
21. Zeichner, S.L., J.Y.Kim&J.C. Alwine. 1991. Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J. Virol. 65: 2436-2444.
22. Zufferey, R. et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72: 9873-9880.
23. Zufferey, R. et al. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73: 2886-2892.
24. Miyoshi, H. et al. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
25. Dull, T. et al. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
26. Fibach, E. & E.A. Rachmilewitz. 1993. The two-step liquid culture: anovel procedure for studying maturation ofhuman normal and pathological erythroid precursors. Stem Cells 11(Suppl 1): 36-41.